[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356599-105":59,"doc-detail-356599-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","shaping-tumor-microenvironment-by-amplifying-the-complement-cascade-for-improved-immune-response-in-pancreatic-cancer-model","Shaping Tumor Microenvironment by Amplifying the Complement Cascade for Improved Immune Response in Pancreatic Cancer Model","","Antibodies against galactose-α-1,3-galactose (αGal) are abundant in humans and are exploited in cancer immunotherapy, in part through complement activation. This work enhances the response by expressing properdin [factor P (FP)], the only known positive complement regulator, as a membrane-anchored form on pancreatic cancer cells. The study shows increased C3 deposition and stronger complement-dependent cytotoxicity with human complement, delayed tumor growth in an immunized Ggta1 knockout mouse model, and remodeling of the tumor microenvironment. Engineering FP to form an artificial C3 convertase-binding site and adding an oligomerization domain improves killing and monocyte-mediated phagocytosis in a human whole-blood loop model, indicating that amplified complement activation can reshape the TME in pancreatic cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/shaping-tumor-microenvironment-by-amplifying-the-complement-cascade-for-improved-immune-response-in-pancreatic-cancer-model/356599/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/shaping-tumor-microenvironment-by-amplifying-the-complement-cascade-for-improved-immune-response-in-pancreatic-cancer-model/356599.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does this study enhance αGal-based cancer immunotherapy?","Question",{"text":112,"@type":113},"It increases complement activation by expressing membrane-anchored properdin (mFP) on pancreatic cancer cells, thereby strengthening αGal-mediated complement activity and CDC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What were the key in vitro and in vivo outcomes of mFP expression?",{"text":117,"@type":113},"Ectopic mFP increased C3 deposition in vitro and enhanced complement-dependent cytotoxicity with human complement, while mFP expression significantly delayed tumor growth in an immunized Ggta1 knockout mouse model.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the engineered properdin design affect therapeutic performance?",{"text":121,"@type":113},"Reconfiguring mFP to create an artificial C3 convertase binding site and adding an intracellular oligomerization domain improved target cell killing and monocyte-mediated phagocytosis in a human whole-blood loop model.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356599,1790201324,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Shaping Tumor Microenvironment by Amplifying the Complement Cascade for Improved Immune Response in Pancreatic Cancer Model  \nMenghan Gao1, Soultana Kechagia1, Mohanraj Ramachandran1, Vivek Anand Manivel1, Nadir Kadri2, Beatrice-Ana Cicortas2, Chuan Jin1, and Di Yu1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Antibodies against galactose-α-1,3-galactose (αGal) are among the most abundant natural antibodies in humans and have been exploited in cancer immunotherapy, with their efficacy partly attributed to complement activation. We aim to enhance this response by employing properdin [also known as factor P (FP)], the only known positive complement regulator. We expressed a membrane-anchored properdin (mFP) on mouse and human pancreatic cancer cells and assessed its ability to enhance αGalmediated complement activation. We showed here that ectopic expression of mFP on Panc02 cells increased the deposition level of C3 in vitro and induced more potent complement-dependent cytotoxicity in the presence of human complement source. In an immunized Ggta1 knockout mouse model, which has circulating anti-αGal antibodies as a mimicry of the human system, mFP expression conferred significantly delayed tumor growth and was\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | associated with pronounced remodeling of the immune landscape in the tumor microenvironment (TME) . Specifically, we observed a marked increase in conventional type 1 dendritic cells, a reduction in tumor-associated monocytes/macrophages with a shift toward a pro-inflammatory phenotype, and a transition of CD8+ T cells toward a progenitor-exhausted state. Reconfiguring the structure of mFP to create an artificial C3 convertase binding site and incorporating an intracellular oligomerization domain improved target cell killing and monocyte-mediated phagocytosis ina human whole-blood loop model. These findings suggest that amplifying complement activation can delay tumor growth and alter the TME in the context of a murine pancreatic cancer model. Furthermore, we have developed a novel membranebound oligomerized FP functional unit, which effectively elicits robust complement activation. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nCancer immunotherapy leverages the body’s own immune system to identify, attack, and eradicate cancer cells. It is a rapidly expanding field with a diverse array of innovative strategies. Approaches leveraging xenogeneic rejection mediated by pre-existing natural antibodies against galactose-α-1,3-galactose (αGal) epitopes have been utilized for cancer immunotherapy (1–3). αGal is a glycol modification catalyzed by glycoprotein α-1,3-galactosyltransferase (GGTA1), which is universally present on mammal cells except for humans, apes, and Old World monkeys (1) . During evolution, humans lost the gene GGTA1, instead, humans developed a high titer of anti-αGal antibodies, constitu","cbCaijTGRROTEG5Z","https://ap.wps.com/l/cbCaijTGRROTEG5Z","pdf",3717553,11,"English","# Introduction\n## Cancer immunotherapy and αGal-mediated complement activation\n## Properdin (factor P) as a positive complement regulator\n## Rationale and hypothesis for enhancing CDC using properdin","[{\"question\":\"How does this study enhance αGal-based cancer immunotherapy?\",\"answer\":\"It increases complement activation by expressing membrane-anchored properdin (mFP) on pancreatic cancer cells, thereby strengthening αGal-mediated complement activity and CDC.\"},{\"question\":\"What were the key in vitro and in vivo outcomes of mFP expression?\",\"answer\":\"Ectopic mFP increased C3 deposition in vitro and enhanced complement-dependent cytotoxicity with human complement, while mFP expression significantly delayed tumor growth in an immunized Ggta1 knockout mouse model.\"},{\"question\":\"How did the engineered properdin design affect therapeutic performance?\",\"answer\":\"Reconfiguring mFP to create an artificial C3 convertase binding site and adding an intracellular oligomerization domain improved target cell killing and monocyte-mediated phagocytosis in a human whole-blood loop model.\"}]","Shaping Tumor Microenvironment by Amplifying the Complement Cascade for Improved Immune Response in Pancreatic Cancer Model | PDF",1790126163,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07901e2ed7c9da6541c85c22808f9354.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7bc442d9eb9361126903f755988cab9c.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50d77011bcd9076e020662743d160cc1.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff45f3b26928a867df8478e61e1303c2.webp",980,1311]